Kyn Therapeutics is developing a novel approach to target both IDO and TDO mediated immunosuppression through enzymatic degradation of kynurenine systemically and in the tumor microenvironment. Inhibiting the IDO/TDO pathway is expected to have broad application across many tumor types.
- Mark Manfredi, PhD Chief Scientific Officer
- Michelle Zhang, PhD VP, Research and Development
- Karen McGovern, PhD VP, Translational Research
- Silvia Coma, PharmD. PhD Principal Scientist